The purpose of this study is to evaluate whether the addition of a drug called tivozanib to another drug, pembrolizumab, is better than the usual approach (pembrolizumab alone) for treating advanced kidney cancer. Specifically, researchers aim to determine whether adding tivozanib to the usual treatment can prevent the cancer from returning and prolong life for patients with kidney cancer who have had all disease removed by surgery and/or radiation or ablation. Pembrolizumab is an immunotherapy that allows the body’s immune system to work against tumor cells. Participants will be randomly assigned to 1 of 2 groups. One group will receive the usual drug alone (pembrolizumab), and the other group will receive tivozanib plus pembrolizumab. Tivozanib is a medication that targets blood vessels and is approved by the U.S. Food and Drug Administration (FDA) for kidney cancer that has not been removed by surgery, but its use in this study is considered investigational.
What is the full name of this clinical trial?
A032201: Short TeRm Intensified Pembrolizumab and Tivozanib for High-risk renal cell carcinoma IRB#4368